BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 14521422)

  • 1. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).
    Remiszewski SW; Sambucetti LC; Bair KW; Bontempo J; Cesarz D; Chandramouli N; Chen R; Cheung M; Cornell-Kennon S; Dean K; Diamantidis G; France D; Green MA; Howell KL; Kashi R; Kwon P; Lassota P; Martin MS; Mou Y; Perez LB; Sharma S; Smith T; Sorensen E; Taplin F; Trogani N; Versace R; Walker H; Weltchek-Engler S; Wood A; Wu A; Atadja P
    J Med Chem; 2003 Oct; 46(21):4609-24. PubMed ID: 14521422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity.
    Wang H; Yu N; Song H; Chen D; Zou Y; Deng W; Lye PL; Chang J; Ng M; Sun ET; Sangthongpitag K; Wang X; Wu X; Khng HH; Fang L; Goh SK; Ong WC; Bonday Z; Stünkel W; Poulsen A; Entzeroth M
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1403-8. PubMed ID: 19181524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
    Mahboobi S; Sellmer A; Höcher H; Garhammer C; Pongratz H; Maier T; Ciossek T; Beckers T
    J Med Chem; 2007 Sep; 50(18):4405-18. PubMed ID: 17691763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole-C2 and/or -C4 substitutions on biological activity.
    Mai A; Massa S; Cerbara I; Valente S; Ragno R; Bottoni P; Scatena R; Loidl P; Brosch G
    J Med Chem; 2004 Feb; 47(5):1098-109. PubMed ID: 14971890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors.
    Kim DK; Lee JY; Kim JS; Ryu JH; Choi JY; Lee JW; Im GJ; Kim TK; Seo JW; Park HJ; Yoo J; Park JH; Kim TY; Bang YJ
    J Med Chem; 2003 Dec; 46(26):5745-51. PubMed ID: 14667227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors.
    Thaler F; Colombo A; Mai A; Amici R; Bigogno C; Boggio R; Cappa A; Carrara S; Cataudella T; Fusar F; Gianti E; di Ventimiglia SJ; Moroni M; Munari D; Pain G; Regalia N; Sartori L; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C; Varasi M
    J Med Chem; 2010 Jan; 53(2):822-39. PubMed ID: 20017493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
    Price S; Bordogna W; Bull RJ; Clark DE; Crackett PH; Dyke HJ; Gill M; Harris NV; Gorski J; Lloyd J; Lockey PM; Mullett J; Roach AG; Roussel F; White AB
    Bioorg Med Chem Lett; 2007 Jan; 17(2):370-5. PubMed ID: 17095213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures.
    Mai A; Massa S; Ragno R; Cerbara I; Jesacher F; Loidl P; Brosch G
    J Med Chem; 2003 Feb; 46(4):512-24. PubMed ID: 12570373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
    Bouchain G; Leit S; Frechette S; Khalil EA; Lavoie R; Moradei O; Woo SH; Fournel M; Yan PT; Kalita A; Trachy-Bourget MC; Beaulieu C; Li Z; Robert MF; MacLeod AR; Besterman JM; Delorme D
    J Med Chem; 2003 Feb; 46(5):820-30. PubMed ID: 12593661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824.
    Atadja P; Hsu M; Kwon P; Trogani N; Bhalla K; Remiszewski S
    Novartis Found Symp; 2004; 259():249-66; discussion 266-8, 285-8. PubMed ID: 15171259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies.
    Ragno R; Mai A; Massa S; Cerbara I; Valente S; Bottoni P; Scatena R; Jesacher F; Loidl P; Brosch G
    J Med Chem; 2004 Mar; 47(6):1351-9. PubMed ID: 14998325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.
    Komatsu Y; Tomizaki KY; Tsukamoto M; Kato T; Nishino N; Sato S; Yamori T; Tsuruo T; Furumai R; Yoshida M; Horinouchi S; Hayashi H
    Cancer Res; 2001 Jun; 61(11):4459-66. PubMed ID: 11389076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes.
    Drummond DC; Marx C; Guo Z; Scott G; Noble C; Wang D; Pallavicini M; Kirpotin DB; Benz CC
    Clin Cancer Res; 2005 May; 11(9):3392-401. PubMed ID: 15867240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
    Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
    Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
    Lee S; Shinji C; Ogura K; Shimizu M; Maeda S; Sato M; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4895-900. PubMed ID: 17588744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor.
    Kim DH; Lee J; Kim KN; Kim HJ; Jeung HC; Chung HC; Kwon HJ
    Biochem Biophys Res Commun; 2007 Apr; 356(1):233-8. PubMed ID: 17353008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
    Moffat D; Patel S; Day F; Belfield A; Donald A; Rowlands M; Wibawa J; Brotherton D; Stimson L; Clark V; Owen J; Bawden L; Box G; Bone E; Mortenson P; Hardcastle A; van Meurs S; Eccles S; Raynaud F; Aherne W
    J Med Chem; 2010 Dec; 53(24):8663-78. PubMed ID: 21080647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of 4-[(s-triazin-2-ylamino)methyl]-N-(2-aminophenyl)-benzamides and their analogues as a novel class of histone deacetylase inhibitors.
    Paquin I; Raeppel S; Leit S; Gaudette F; Zhou N; Moradei O; Saavedra O; Bernstein N; Raeppel F; Bouchain G; Fréchette S; Woo SH; Vaisburg A; Fournel M; Kalita A; Robert MF; Lu A; Trachy-Bourget MC; Yan PT; Liu J; Rahil J; MacLeod AR; Besterman JM; Li Z; Delorme D
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1067-71. PubMed ID: 18160287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.